Deutsche Bank Sees Short And Long Term Upside In Regulus’ Pipeline Assets
In a research report released Monday, Deutsche Bank analyst Alethia Young maintained a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) with a $30 price target, which implies an upside of 70% from current levels.
Young commented: “We see dramatic LT upside as this early platform story begins to play out. If both RG-101 and RG- 012 were successful, our Regulus FV is $99/share.”
He added, “We assume peak HCV sales of $1.5B. We assume peak AS sales of $1.2B to Regulus (assuming profit split with Sanofi). At 100% success, RG-101 is worth $37/sh while AS is worth $59/sh. Regulus has the potential to move assets into the clinic at an annual rate like Alnylam and ISIS w/this kind of technology.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Alethia Young has a total average return of 2.4% and a 55.6% success rate. Young has a average return when recommending RGLS, and is ranked #1639 out of 3377 analysts.